[{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"SJ733","moa":"||PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ GHIT Fund","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GHIT Fund"},{"orgOrder":0,"company":"R. Kiplin Guy","sponsor":"GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SJ733","moa":"||PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"R. Kiplin Guy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R. Kiplin Guy \/ GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica","highestDevelopmentStatusID":"8","companyTruncated":"R. Kiplin Guy \/ GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica"}]

Find Clinical Drug Pipeline Developments & Deals for SJ733

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated with SJ733 for the treatment of P.vivax malaria.

                          Product Name : Arakoda

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 08, 2024

                          Lead Product(s) : Tafenoquine Succinate,SJ733

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The financing will be used to develop a radical cure for P. vivax malaria. SJ000557733 (SJ733), an antimalarial drug candidate, has completed a Phase IIa trial for single administration and has shown efficacy and tolerability against P. vivax malaria.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : SJ733,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GHIT Fund

                          Deal Size : $5.4 million

                          Deal Type : Financing

                          blank

                          03

                          R. Kiplin Guy

                          Country arrow
                          EPSC
                          Not Confirmed

                          R. Kiplin Guy

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2021

                          Lead Product(s) : SJ733,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          St. Jude Children's Research Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          St. Jude Children's Research Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 22, 2016

                          Lead Product(s) : SJ733,Cobicistat

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Medicines for Malaria Venture | Eisai Inc | GHIT Fund

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank